tiprankstipranks
Trending News
More News >

RedHill Biopharma Initiates Phase 2 Prostate Cancer Study

Story Highlights
RedHill Biopharma Initiates Phase 2 Prostate Cancer Study

Don’t Miss TipRanks’ Half-Year Sale

An announcement from RedHill Biopharma ( (RDHL) ) is now available.

On July 1, 2025, RedHill Biopharma announced the initiation of patient recruitment for a Phase 2 study evaluating the combination of opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). Sponsored by ANZUP and supported by Bayer and Ramsay Hospital Research Foundation, the study aims to assess the efficacy of this combination in overcoming resistance to standard androgen receptor pathway inhibition treatments. The study will recruit 60 participants across Australia and New Zealand, utilizing a precision medicine approach with the PCPro lipid biomarker test to identify patients most likely to benefit. This marks a significant step in RedHill’s oncology development, potentially enhancing its market position in the prostate cancer treatment landscape.

Spark’s Take on RDHL Stock

According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.

The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.

To see Spark’s full report on RDHL stock, click here.

More about RedHill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel, and Raleigh, NC. The company focuses on developing and commercializing proprietary drugs for the treatment of gastrointestinal diseases, infectious diseases, and cancer. RedHill’s pipeline includes investigational drugs for various indications, including oncology and pandemic preparedness.

Average Trading Volume: 222,826

Technical Sentiment Signal: Sell

Current Market Cap: $4.26M

For detailed information about RDHL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1